Akero Therapeutics Stock Price, News & Analysis

On November 12, 2021, Akero Therapeutics (Nasdaq: AKRO) reported promising results from a post-hoc analysis of its Phase 2a BALANCED study of efruxifermin (EFX) for non-alcoholic steatohepatitis (NASH). After 16 weeks, 87% (35 of 40) of EFX-treated patients showed improvements in steatohepatitis, while 80% (32 of 40) demonstrated fibrosis improvement. The findings were presented at The Liver Meeting of the American Association for the Study of Liver Diseases. Akero is optimistic about the upcoming Phase 2b studies and the potential for EFX to become a leading treatment for NASH.

Akero Therapeutics (AKRO) reported its Q3 2021 financial results, highlighting a cash position of $215.1 million, sufficient to fund operations into Q3 2023. The company is progressing in two Phase 2b clinical trials for efruxifermin (EFX) targeting non-alcoholic steatohepatitis (NASH). Notably, the FDA granted Fast Track designation for EFX, enabling more frequent interactions and potential priority review. Q3 research and development expenses increased to $19.5 million, with total operating expenses at $24.4 million, compared to $21.5 million in Q3 2020.

Akero Therapeutics (Nasdaq: AKRO) announced participation in a fireside chat at the Jefferies London Healthcare Conference, available for on-demand viewing on November 18 at 3:00 a.m. EST. Known for its focus on serious metabolic diseases, Akero is developing efruxifermin (EFX), a potential best-in-class treatment for non-alcoholic steatohepatitis (NASH), which currently lacks approved therapies. EFX is undergoing evaluation in two Phase 2b trials: HARMONY and SYMMETRY.

Akero Therapeutics (NASDAQ: AKRO) announced that the FDA has granted Fast Track designation for its lead program, efruxifermin (EFX), aimed at treating non-alcoholic steatohepatitis (NASH). This designation facilitates quicker development and potential priority review of the drug. Currently, EFX is in two Phase 2b clinical trials targeting advanced fibrosis and cirrhosis in NASH patients. The company reported promising clinical data, including a 50% improvement in fibrosis for half of F2/F3 patients. NASH is expected to affect 27 million Americans by 2030, with no approved therapies available.

Akero Therapeutics (Nasdaq: AKRO) announced that Tim Rolph, Chief Scientific Officer and Co-Founder, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, at 12:00 p.m. (ET). The presentation will be available via a live webcast on the company's investor relations website. Akero is focused on developing treatments for non-alcoholic steatohepatitis (NASH), with its lead candidate, efruxifermin (EFX), currently undergoing a Phase 2b clinical trial. EFX offers a promising treatment approach for this complex disease.

Akero Therapeutics (Nasdaq: AKRO) will present at the Morgan Stanley Virtual Global Healthcare Conference on September 15, 2021, at 11:45 a.m. (ET). The presentation will highlight the company's innovative approach to treating non-alcoholic steatohepatitis (NASH) with its investigational drug, efruxifermin (EFX). EFX aims to offer potential benefits as a best-in-class medicine, with ongoing Phase 2b trials evaluating its effectiveness in patients with varying fibrosis stages. A live webcast of the presentation will be available on Akero's investor relations website.

Akero Therapeutics (Nasdaq: AKRO) reported its Q2 2021 financial results, highlighting the ongoing development of efruxifermin (EFX) for treating non-alcoholic steatohepatitis (NASH). The company has initiated a second Phase 2b clinical trial for late-stage cirrhotic NASH patients, following significant progress in previous trials, including a published study demonstrating fibrosis regression. As of June 30, 2021, Akero's cash and marketable securities totaled $230 million, expected to support operations through Q3 2023. R&D expenses rose to $24 million, reflecting increased costs related to EFX programs.

Akero Therapeutics (Nasdaq: AKRO) announced the appointment of Judy Chou, Ph.D., to its board of directors as an independent director. Dr. Chou brings 25 years of biotech experience, including roles at Bayer Pharmaceuticals and AltruBio, where she managed drug development and biomanufacturing. Her strategic insights are expected to aid Akero’s lead drug, efruxifermin, which is in a Phase 2b clinical trial for non-alcoholic steatohepatitis (NASH). This appointment reflects Akero's commitment to advancing innovative therapies in a critical therapeutic area.

Akero Therapeutics announced the publication of results from its Phase 2a BALANCED trial of efruxifermin (EFX) in the treatment of non-alcoholic steatohepatitis (NASH), showing significant reductions in liver fat and improvement in fibrosis after just 16 weeks of treatment. In the study, 48% of EFX patients normalized liver fat levels versus 5% in the placebo group. EFX demonstrated improved metabolic markers and was generally well tolerated, with minimal serious adverse events reported. The trial results contribute to the development of potentially groundbreaking NASH therapies.